PureTech’s interim results highlight a busy six months with multiple portfolio financings and development progression with 20 clinical trials ongoing. We continue to expect five proof-of-concept readouts as well as multiple pivotal or registration trial readouts, along with a potential product launch (Akili) over the next 24 months. PureTech is well financed with a consolidated cash balance of $297.4m at the period end. PureTech is trading at an EV/portfolio value of 0.7x, an undeserved discount ....
07 Sep 2016
N+1 Singer - PureTech - Interim results highlight upcoming newsflow
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - PureTech - Interim results highlight upcoming newsflow
PureTech Health PLC (PRTC:LON) | 224 0 0.0% | Mkt Cap: 605.9m
- Published:
07 Sep 2016 -
Author:
Sheena Berry -
Pages:
3
PureTech’s interim results highlight a busy six months with multiple portfolio financings and development progression with 20 clinical trials ongoing. We continue to expect five proof-of-concept readouts as well as multiple pivotal or registration trial readouts, along with a potential product launch (Akili) over the next 24 months. PureTech is well financed with a consolidated cash balance of $297.4m at the period end. PureTech is trading at an EV/portfolio value of 0.7x, an undeserved discount ....